Form 4: 89bio CMO Sells Shares for Tax Withholding
Insider Transaction Report
89bio's Chief Medical Officer, Harry H. Mansbach, disposed of 7,680 common shares valued at $9.16 per share to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Harry H. Mansbach, Chief Medical Officer of 89bio, Inc. (ETNB), reported a transaction on August 1, 2025.
- The transaction involved the disposition of 7,680 shares of 89bio common stock.
- These shares were sold at a price of $9.16 per share.
- The purpose of the disposition was to cover estimated tax withholding obligations arising from the vesting of restricted stock units.
- Following this transaction, Mr. Mansbach beneficially owns 302,656 shares of 89bio common stock directly.
Sentiment
Score: 5
Explanation: The transaction is neutral as it represents a routine tax withholding event associated with equity compensation vesting, rather than a discretionary sale or purchase.
Positives
- The transaction indicates the vesting of restricted stock units, which implies continued employment and equity compensation for a key executive.
Negatives
- The disposition of shares, even for tax purposes, represents a reduction in the executive's direct ownership stake.
Future Outlook
This filing is a routine insider transaction report and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing is a standard disclosure of an insider transaction and does not provide broader industry context or trends. It reflects a routine equity compensation event for an executive within the biotechnology sector.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction by an executive to cover tax obligations, not a signal of a change in confidence or strategy.
- Employees: No direct impact beyond the executive involved.
Key Dates
| Date | Description |
|---|---|
| 08/01/2025 | Date of transaction (disposition of shares). |
| 08/05/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
89bio, ETNB, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Chief Medical Officer, Harry H. Mansbach
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.